title: Cypher versus Taxus: the stent war.
abstract: Cypher (sirolimus-eluting stent) and Taxus (paclitaxel-eluting stent) have been approved for use in percutaneous coronary intervention. Both of the stents have shown superiority over bare metal stents in reducing major adverse cardiac events, restenosis rates and target vessel revascularisation. Results of clinical trials with head-to-head comparison of Taxus and Cypher stents in patients with obstructive coronary artery diseases have recently been reported. This review compares the performance of Cypher and Taxus stents as noted in observational studies and clinical trials in various types of coronary artery lesions.
authors.affiliation: Postgraduate Institute of Medical Education and Research, Department of Pharmacology, Chandigarh, 160012, India.
authors.forename: Nusrat
authors.initials: N
authors.lastname: Shafiq
authors.forename: Samir
authors.initials: S
authors.lastname: Malhotra
authors.forename: Promila
authors.initials: P
authors.lastname: Pandhi
authors.forename: Ajay
authors.initials: A
authors.lastname: Behl
authors.forename: Yash Paul
authors.initials: YP
authors.lastname: Sharma
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000188:drug therapy / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control*; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control; D048909:Diabetes Complications / Q000188:drug therapy / Q000628:therapy; D004343:Drug Implants; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D015607:Stents; D016896:Treatment Outcome
chemical_list: D004343:Drug Implants; D017239:Paclitaxel; D020123:Sirolimus